Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Ascendis Pharma A/S	Arrowhead Pharmaceuticals	Ionis Pharmaceuticals	ACADIA Pharmaceuticals	United Therapeutics
Symbol	NASDAQ:ASND	NASDAQ:ARWR	NASDAQ:IONS	NASDAQ:ACAD	NASDAQ:UTHR
Price Information
Current Price	$132.37	$71.22	$42.44	$20.62	$205.66
52 Week Range	Buy	Buy	Hold	Hold	Buy
MarketRank™
Overall Score	1.5	1.3	1.6	1.9	1.5
Analysis Score	3.5	2.4	4.1	4.2	2.5
Community Score	2.6	2.5	2.3	3.2	2.2
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	1.7	1.7	1.7	1.7
Earnings & Valuation Score	0.6	0.0	0.0	0.6	1.3
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Hold	Buy
Consensus Price Target	$192.22	$85.31	$57.45	$32.76	$219.57
% Upside from Price Target	45.22% upside	19.78% upside	35.38% upside	58.90% upside	6.76% upside
Trade Information
Market Cap	$7.09 billion	$7.37 billion	$5.98 billion	$3.34 billion	$9.32 billion
Beta	0.77	1.62	1.42	1.44	0.52
Average Volume	208,665	795,625	1,231,101	2,192,327	383,102
Sales & Book Value
Annual Revenue	$14.98 million	$87.99 million	$1.12 billion	$339.08 million	$1.45 billion
Price / Sales	474.96	84.01	5.32	9.73	6.32
Cashflow	N/A	N/A	$1.73 per share	N/A	N/A
Price / Cash	N/A	N/A	24.55	N/A	N/A
Book Value	$15.87 per share	$4.51 per share	$11.98 per share	$4.54 per share	$63.36 per share
Price / Book	8.34	15.79	3.54	4.54	3.25
Profitability
Net Income	$-244,180,000.00	$-84,550,000.00	$303.26 million	$-235,260,000.00	$-104,500,000.00
EPS	($5.25)	($0.84)	$2.08	($1.60)	($2.39)
Trailing P/E Ratio	N/A	N/A	88.42	N/A	19.46
Forward P/E Ratio	N/A	N/A	N/A	N/A	17.74
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-4,042.79%	-96.09%	7.82%	-63.92%	33.25%
Return on Equity (ROE)	-55.72%	-17.37%	6.57%	-40.35%	15.48%
Return on Assets (ROA)	-49.42%	-15.19%	3.39%	-34.72%	11.31%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.51%	N/A	0.24%
Current Ratio	14.80%	7.92%	10.37%	7.95%	7.22%
Quick Ratio	14.80%	7.92%	10.28%	7.86%	6.88%
Ownership Information
Institutional Ownership Percentage	N/A	65.52%	84.14%	93.54%	90.09%
Insider Ownership Percentage	40.00%	4.00%	2.40%	27.70%	10.90%
Miscellaneous
Employees	482	232	757	601	950
Shares Outstanding	53.75 million	103.79 million	140.86 million	160.05 million	44.54 million
Next Earnings Date	5/18/2021 (Estimated)	5/4/2021 (Confirmed)	5/5/2021 (Confirmed)	5/5/2021 (Confirmed)	5/5/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	United Therapeutics (NASDAQ:UTHR) Hits New 12-Month High at $212.54 americanbankingnews.com - April 22 at 1:40 PM
	United Therapeutics Co. (NASDAQ:UTHR) Expected to Announce Earnings of $2.60 Per Share americanbankingnews.com - April 22 at 12:28 PM
	Pre-earnings Momentum Trade With a Technical Trigger in United Therapeutics Corp cmlviz.com - April 21 at 6:35 PM
	Wedbush Stick to Their Buy Rating for United Therapeutics investing.com - April 21 at 1:35 PM
	United Therapeutics (NASDAQ:UTHR) Shares Gap Up to $203.84 americanbankingnews.com - April 21 at 11:02 AM
	United Therapeutics takes latest step in aggressive push to launch more products bizjournals.com - April 19 at 1:59 PM
	Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA markets.businessinsider.com - April 19 at 8:56 AM
	Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI(TM) With New Drug Application Submitted to the FDA marketwatch.com - April 19 at 8:56 AM
	Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New ... apnews.com - April 19 at 8:56 AM
	United Therapeutics (NASDAQ:UTHR) Sets New 1-Year High at $205.52 americanbankingnews.com - April 17 at 12:12 PM
	United Therapeutics (NASDAQ:UTHR) Sets New 52-Week High on Analyst Upgrade americanbankingnews.com - April 8 at 4:22 PM
	United Therapeutics (NASDAQ:UTHR) Given New $212.00 Price Target at JPMorgan Chase & Co. americanbankingnews.com - April 8 at 10:10 AM
	JPMorgan Chase & Co. Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $212.00 marketbeat.com - April 8 at 8:13 AM
	Is UTHR Stock A Buy or Sell? finance.yahoo.com - April 6 at 6:55 PM
	United Therapeutics (UTHR) Gains on Tyvaso Label Expansion finance.yahoo.com - April 5 at 12:53 PM
	This Pharma Can Breathe New Life Into Your Portfolio finance.yahoo.com - April 2 at 9:10 AM
	United Therapeutics Receives FDA Approval For Tyvaso Therapy; Shares Pop 15% finance.yahoo.com - April 2 at 9:10 AM
	United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR) americanbankingnews.com - April 1 at 7:55 PM
	United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD streetwisereports.com - April 1 at 6:53 PM
	Wingstop, Guess rise; CarMax, Emergent BioSolutions fall marketbeat.com - April 1 at 4:31 PM
	United Therapeutics Jumps as FDA Clears Hypertension Drug thestreet.com - April 1 at 1:52 PM
	United Therapeutics (NASDAQ:UTHR) Hits New 12-Month High at $186.90 americanbankingnews.com - April 1 at 10:40 AM
	FDA approves inhaled pulmonary hypertension treatment from United Therapeutics drugdeliverybusiness.com - April 1 at 8:50 AM
	United Therapeutics: FDA Approves Tyvaso For PH-ILD - Quick Facts nasdaq.com - April 1 at 8:50 AM
	UTHR Aug 2021 160.000 put ca.finance.yahoo.com - March 27 at 3:16 PM
	UTHR May 2021 110.000 call ca.finance.yahoo.com - March 27 at 9:52 AM
	UTHR Aug 2021 200.000 put ca.finance.yahoo.com - March 27 at 9:52 AM

Date	Company	Brokerage	Action
3/30/2021	Ascendis Pharma A/S	Oppenheimer	Downgrade
3/18/2021	Ascendis Pharma A/S	Canaccord Genuity	Boost Price Target
3/17/2021	Ascendis Pharma A/S	Credit Suisse Group	Lower Price Target
3/11/2021	Ascendis Pharma A/S	Stifel Nicolaus	Initiated Coverage
12/17/2020	Ascendis Pharma A/S	Berenberg Bank	Initiated Coverage
11/13/2020	Ascendis Pharma A/S	Morgan Stanley	Boost Price Target
11/12/2020	Ascendis Pharma A/S	Wells Fargo & Company	Boost Price Target
11/12/2020	Ascendis Pharma A/S	SVB Leerink	Boost Price Target
9/30/2020	Ascendis Pharma A/S	Wedbush	Boost Price Target
9/14/2020	Ascendis Pharma A/S	JPMorgan Chase & Co.	Initiated Coverage
5/20/2020	Ascendis Pharma A/S	CSFB	Boost Price Target
2/8/2021	Arrowhead Pharmaceuticals	Citigroup	Boost Price Target
2/8/2021	Arrowhead Pharmaceuticals	B. Riley	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	Piper Sandler	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	Chardan Capital	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	HC Wainwright	Boost Price Target
12/21/2020	Arrowhead Pharmaceuticals	Robert W. Baird	Downgrade
12/15/2020	Arrowhead Pharmaceuticals	UBS Group	Initiated Coverage
11/24/2020	Arrowhead Pharmaceuticals	Royal Bank of Canada	Boost Price Target
11/24/2020	Arrowhead Pharmaceuticals	Cantor Fitzgerald	Boost Price Target
11/19/2020	Arrowhead Pharmaceuticals	Smith Barney Citigroup	Initiated Coverage
11/19/2020	Arrowhead Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
3/29/2021	Ionis Pharmaceuticals	Needham & Company LLC	Lower Price Target
3/29/2021	Ionis Pharmaceuticals	BMO Capital Markets	Lower Price Target
3/23/2021	Ionis Pharmaceuticals	Barclays	Lower Price Target
12/15/2020	Ionis Pharmaceuticals	Cowen	Upgrade
4/13/2021	ACADIA Pharmaceuticals	The Goldman Sachs Group	Reiterated Rating
4/13/2021	ACADIA Pharmaceuticals	Jefferies Financial Group	Reiterated Rating
4/13/2021	ACADIA Pharmaceuticals	Mizuho	Reiterated Rating
4/5/2021	ACADIA Pharmaceuticals	Raymond James	Downgrade
3/16/2021	ACADIA Pharmaceuticals	Bank of America	Reiterated Rating
3/15/2021	ACADIA Pharmaceuticals	Guggenheim	Reiterated Rating
1/20/2021	United Therapeutics	LADENBURG THALM/SH SH	Boost Price Target

(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources